Jasper Therapeutics (NASDAQ:JSPR) Upgraded by Piper Sandler to Strong-Buy Rating

Piper Sandler upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. Finally, TD Cowen downgraded shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.57.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $0.82 on Wednesday. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $3.14. The company has a market capitalization of $23.07 million, a price-to-earnings ratio of -0.26 and a beta of 3.02. The stock has a fifty day moving average of $0.58 and a two-hundred day moving average of $0.91.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP boosted its stake in Jasper Therapeutics by 86.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after buying an additional 1,234,567 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after acquiring an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC purchased a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $3,291,000. Millennium Management LLC boosted its position in shares of Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of Jasper Therapeutics in the third quarter worth approximately $2,475,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.